1,2-Dimethyl-4-oxaspiro[2.4]heptan-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢呋喃
• 英文名称: 1,2-Dimethyl-4-oxaspiro[2.4]heptan-6-one
• 英文别名: 1,2-dimethyl-4-oxaspiro[2.4]heptan-6-one
• 化学式: C₈H₁₂O₂
• 分子量: 140.18
• InChiKey: YAPGAMVIKCFXAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140142119A1

  公开（公告）日：2014-05-22

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样品或患者中流感病毒复制的方法，减少生物样品或患者中流感病毒的数量，以及治疗患者的流感的方法，包括向所述生物样品或患者投予有效量的由结构式（I）表示的化合物或其药学上可接受的盐，其中结构式（IA）的值如此处所述。所述化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如此处所述。药物组合物包括有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• Inhibitors of influenza viruses replication
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10039762B2

  公开（公告）日：2018-08-07

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的结构式（I）所代表的化合物： 或其药学上可接受的盐，其中结构式（IA）的值如本文所述。一种化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如本文所述。药物组合物包含有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。